🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — May 14, 2026

Across 41 filings in the USA S&P 500 Technology stream, a dominant theme is robust revenue acceleration in select tech, space, and comms firms (e.g., Applied Materials +11% YoY to $7.91B, Intuitive Machines 3x YoY to $186.7M, GameSquare +95% YoY to $14.5M), contrasted by profitability volatility and cash burn pressures amid M&A (Iridium $366.7M Aireon deal, Intuitive $800M Lanteris). Period-over-period trends show 7/15 quarterly reporters posting YoY revenue growth averaging +55% (outliers: ImmuCell +28%, RideNow +6.4%), but 6/15 saw net losses widen or emerge (avg -45% net income swing), with margins mixed (Applied +80bps to 49.9%, ImmuCell +340bps to 45%). Institutional 13F snapshots reveal concentrated tech bets (Broadcom $250M Paradigm, Analog Devices $216M Timucuan, TSMC/Amazon ~$20M H Squared), signaling conviction in semis/AI/cloud. Forward-looking catalysts cluster in Q3 2026 (Applied rev ~$8.95B, Iridium deal close), while capital allocation leans shareholder-friendly (Applied div +15% to $0.53). Biotech-adjacent tech like INmune Bio's FDA Fast Track adds upside, but BDC/niche declines (Muzinich income -38% YoY) flag sector divergence. Overall, actionable alpha in growth outperformers pre-earnings/M&A closes, with risks in cash-strapped turnarounds.

13 high priority 28 medium 41 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 14, 2026

The 48 filings from NASDAQ-100 constituents and related entities reveal mixed Q1 2026 results across 15 earnings reporters, with 8/15 showing YoY revenue growth averaging +28% (e.g., ImmuCell +28%, INBS +46%, Intuitive Machines +200%), but persistent net losses in 12/15 amid rising G&A/exploration costs; margin expansions noted in 4/15 (e.g., INBS +370 bps gross margin). Key themes include accretive M&A (Iridium-Aireon adding $100M rev, Intuitive Machines-Lanteris boosting backlog to $1.1B), regulatory wins (TMC NOAA compliance by Q1 2027, INmune Bio FDA Fast Track), and institutional positioning via 13Fs favoring mining/tech (e.g., Mudita heavy in gold/mining, Paradigm in semis). Capital allocation leans conservative with dividend hikes (Applied Materials +15% to $0.53/share) but no buybacks noted; cash burns improved in 6/15 ops cash flow metrics. Portfolio-level trends show metals/biotech outperformance in milestones vs. services revenue softness (Intellinetics -8%). Forward catalysts cluster in H2 2026 (deal closes, trial data), signaling alpha in space/mining amid AI/semicon strength. Overall, bullish on strategic progress offsetting losses, with watch for cash runway in microcaps.

19 high priority 29 medium 48 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 14, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related SPACs/BDCs), dominant themes include SPAC quarterly resilience via trust interest income (10 SPACs averaging +$1.4M net income Q1 2026 despite ops losses and cash burns QoQ 20-67%), active debt markets with refinancings/upsizes (Lumen $2.4B Term B-5, Encore €325M notes), and mixed operating results in financial-adjacent firms (revenue growth in 8/15 ops cos avg +45% YoY skewed by small caps like Lifeway +37%, Karman +51%, but declines in larger like New Fortress -52%, Apartment REIT -4.8%). Period-over-period trends reveal margin expansions in outliers (Lifeway +360bps, Intelligent Bio +380bps to 50.5%) contrasting compressions elsewhere (SpringBig gross -16.8%), with capital allocation favoring debt raises over buybacks/dividends (News Corp $1B program ongoing, Muzinich no distributions). Forward-looking signals positive for growth (Lifeway FY2027 EBITDA $45-50M, Health In Tech scaling in $1T market), but SPAC risks high (Cantor 22M shares redeemed -$234M trust, Vernal going concern). Portfolio-level: Neutral 13Fs (Lord Abbett $30M, Gemsstock $949M energy tilt), bullish catalysts in M&A (Presidio $83M oil/gas), bearish cash burns signal caution; actionable now: Favor debt-access firms, monitor SPAC combos.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 14, 2026

Across 50 filings primarily from small-cap biotechs, medtech, financials, and institutional 13F-HR snapshots (despite Consumer Staples stream focus, data skews pharma/services), Q1 2026 results show mixed performance: 8/15 quarterly reporters achieved revenue growth averaging +28% YoY (e.g., Intelligent Bio +46%, NIQ +11.1%), but 12/15 widened net losses (avg +45% YoY) amid rising opex/R&D, with cash burn improving in 6 cases. Key themes include M&A completion (Apellis acquired by Biogen at $41/share + CVR), positive clinical data (Cellectar 61.8% MRR), financing successes ($140M for Cellectar, $50M loan for Pelthos), and neutral 13F holdings in tech/ETFs signaling steady institutional conviction. Capital allocation leans defensive (dividends at Chicago BDC $0.34/share, reverse splits at Reliance), with forward guidance reaffirmed (NIQ 5-5.3% OCC growth). Portfolio-level trends: margin expansion in 4/10 (Intelligent Bio +380bps), but compression elsewhere; biotech outliers shine on milestones vs deteriorating liquidity in 7 firms (cash down >50% QoQ). Implications: tactical opportunities in catalysts (ASCO June 1), but watch liquidity risks and delistings amid volatile small-caps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 14, 2026

Across the 50 filings in the USA S&P 500 Industrials stream, sentiment skews mixed-positive, driven by robust revenue growth in select industrials and energy-adjacent names like Forgent Power Solutions (+103% YoY to $379M revenue, +308% bookings) and LanzaTech (+26% YoY revenue), contrasting with persistent net losses in biotechs despite R&D progress. Period-over-period trends reveal 8/18 quarterly reporters with YoY revenue growth averaging 52% (outliers: Forgent 103%, Intelligent Bio 46%), but 10/18 showed net loss widening (avg +35% YoY) due to OpEx ramps; margins expanded in 5 cases (e.g., Forgent Adj EBITDA +96% to 22.4%). Institutional 13Fs (17 filings) highlight concentrated ETF exposure and defense industrials like Lockheed Martin ($10.5M in Campion), signaling broad sector conviction. Capital allocation shines with CSX's $5B buyback authorization atop $989M remaining, while M&A (Apellis acquired at $41/share + CVR) and debt raises (Constellation $2.2B notes) bolster liquidity. Forward-looking data flags raised guidances (Forgent FY26 rev +82% YoY midpoint, Hyperion +20%) and catalysts like Cabaletta's mid-2026 data readouts. Portfolio implications: Tactical buys in high-growth industrials amid biotech volatility, monitor June 2026 debt events.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 14, 2026

The S&P 500 Energy sector filings reveal strong shareholder confidence in governance at majors ConocoPhillips and Phillips 66, with near-unanimous approvals for directors, auditors, and exec comp amid rejected independent chair proposal at COP. A wave of 13F-HR disclosures from institutions like Blue Whale Capital ($2.1B portfolio, NVIDIA/Lam top), Fuller & Thaler ($29.7B, industrials focus), and Noked Israel ($677M, semis heavy) shows minimal evident energy exposure in top holdings, suggesting investor sidelining of oil/gas amid tech preference. Apartment Income REIT's Q1 10-Q flags mixed results: revenues -4.8% YoY to $193.7M, net loss $(28.9M) vs prior profit, but operating cash +376% YoY to $39.6M and interest expense -13.5% to $81.2M. No insider trades, M&A, or guidance changes noted across filings; capital allocation subdued with REIT capex -48% YoY to $12.8M. Portfolio-level trend: neutral institutional positioning, positive energy AGM outcomes contrast REIT weakness, implying stable but uninspiring sector momentum into Q2 2026.

2 high priority 10 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — May 14, 2026

Across 50 8-K filings from May 14, 2026, dominant themes include a surge in debt refinancings and issuances totaling over $15B (e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B), signaling robust capital market access amid favorable rates and extending maturities out to 2036. M&A activity highlights consolidation with Apellis Pharmaceuticals fully acquired by Biogen at $41/share + CVR, Iridium's accretive $367M Aireon buy adding $100M annualized revenue, and Presidio's $83M Oklahoma assets deal closing Q3 2026. Leadership transitions are orderly (e.g., RenaissanceRe CFO succession, Selective Insurance CIO retirement), with positive capital returns via CSX's $5B buyback and KeyCorp's $3B program + dividends. Limited period-over-period data shows NeoVolta's nine-month revenue +262% YoY to $13.3M but Q3 flat YoY at $2M and wider $3M net loss, amid residential solar slowdown. Risks cluster in dilutive financings (HyOrc, GridAI) and restructurings (Trinseo's $2B debt cut via Chapter 11), while opportunities emerge in energy acquisitions and SPAC extensions. Sector patterns favor utilities/energy refinancing for balance sheet strength, contrasting mixed sentiment in small-cap tech financings.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 14, 2026

Across 50 SEC filings from May 14, 2026, primarily Q1 2026 10-Qs and 8-Ks, a key theme is robust revenue growth in 12/20 reporting companies averaging 67% YoY (e.g., RenovoRx +186%, Barfresh +92%, Aveanna +15.9%), driven by commercial expansion and segment gains, though offset by widening losses in 8 cases due to rising SG&A/R&D (avg +25% YoY). Biotech and healthcare firms dominate with clinical catalysts (e.g., Corvus Phase 1 success, RenovoRx trial enrollment by June), while telecom (Verizon) and consumer (YETI) show stable financing/debt access. Margin trends mixed: expansions in Enovix (+495% gross profit), compressions in YETI (-210 bps) and Versant (-11% op income). Capital allocation favors repurchases/dividends (Versant $100M buyback, YETI $500M auth increase) amid cash raises ($30M LanzaTech, $150M Cabaletta). Forward guidance raised in 4 firms (Aveanna rev +$40M, YETI sales 7-8%), signaling confidence; DJ30 exposure limited but Verizon's $4B notes positive. Portfolio implication: selective buys in growth biotechs/healthcare with near-term catalysts, caution on expense-heavy small caps; alpha from M&A/turnarounds like Kennedy-Wilson merger.

21 high priority 29 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 14, 2026

Across 50 SEC filings for May 14, 2026, Q1 2026 results reveal polarized performance: strong revenue growth in niche consumer (Lifeway +37% YoY) and biotech (Intelligent Bio +46% YoY), contrasted by sharp declines in energy (New Fortress -52% YoY revenue) and SPACs facing cash burns despite trust interest income (avg +1000% YoY in 8 SPACs). Debt refinancings (Lumen $2.4B Term B-5) and M&A (Presidio $83M oil/gas acquisition) signal financial maneuvers amid mixed sentiment (28/50 mixed/neutral). SPACs dominate with extensions (GP-Act III to Nov 2026) and deficits widening (avg 10% QoQ in 10 filings), while 13Fs highlight institutional bets on biotech/energy (Rhenman healthcare heavy, Gemsstock energy/gold). Capital allocation leans conservative with buybacks (News Corp $1B program) and dividends steady; forward guidance sparse but Lifeway targets $45-50M EBITDA FY2027. Portfolio trend: 12/25 10-Qs show revenue growth >20% YoY but margins mixed (avg +100bps in winners, -200bps losers), implying selective opportunities in growth outliers amid broader caution.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 14, 2026

Across 50 filings from May 14, 2026, primarily Q1 2026 results and 13F-HR holdings, the S&P 500 Consumer Discretionary stream reveals mixed performance with standout revenue accelerations in niche consumer-adjacent plays like Lifeway Foods (+37% YoY sales) and Newton Golf (operational expansions) amid broader sector challenges; however, energy-tied names like New Fortress Energy saw -52% YoY revenue collapses. Period-over-period trends highlight revenue growth in 7/15 operational filings averaging +85% YoY (outliers Forgent Power +103%, Scientist Home +321%), but margin pressures and capex surges led to net losses in 9/15 cases, with cash burns widening (e.g., WhiteFiber -33.8% QoQ cash). Institutional 13F-HRs (20+ filings) show heavy tech/consumer exposure (e.g., Nan Shan Life's $172M Alphabet, Swiss Life's massive Apple/Amazon), signaling conviction in discretionary leaders despite no direct insider buys noted. Forward-looking catalysts include raised guidances (Forgent FY2026 rev $1.35-1.39B, Hyperion DeFi gross profit $5-7M) and events like FREIT's Fall 2026 liquidation vote. Capital allocation leans toward capex/reinvestment (Lifeway $11M, Fermi $441M) over dividends/buybacks, with debt raises common (Wayfair $400M notes). Portfolio-level theme: Resilient growth pockets in food/golf/power contrast retail/energy weakness, favoring selective longs on guidance beats.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 14, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (despite cross-sector inclusions), Q1 2026 results from 10+ companies reveal robust revenue growth averaging +150% YoY in growth-oriented firms like Lifeway (+37%), Scientist Home (+321%), and UMeWorld (+85,000%), but persistent margin compression (-1,200bps avg in 5/8 cases) and opex explosions (+500% avg) drove wider net losses in 7/10, with cash burn accelerating and positions declining QoQ in 8/10 (e.g., Cellectar -37%, Senti -46%). Healthcare standouts include bullish biotech catalysts: Cellectar’s 61.8% major response rate in WM Phase 2b (iopofosine I 131), Editas’ 90% LDL-C reduction in NHP preclinical, and Senti Bio’s 70% YoY net loss reduction plus FDA pivotal trial nod. Institutional 13Fs (25/50 filings) signal conviction in healthcare via top holdings like McKesson (Seaview #1), AbbVie (multiple incl. Weaver, HRT, MFS), and biotechs Mineralys/Phathom (Catalys 93% portfolio). Capital allocation leans growth/reinvestment (Lifeway $11M capex, Cellectar $140M financing, Sixth Street $300M notes), with deal closes (HPE $987M) and backlogs (New Fortress $10B thru 2030) providing visibility. Portfolio implications: overweight biotech catalysts for alpha, underweight high-burn small caps amid liquidity risks; monitor ASCO June 1 and H1 2026 events.

11 high priority 39 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 14, 2026

Across 11 DEF 14A proxy statements filed around May 14, 2026, dominant themes include director elections (9/11 filings), advisory votes on executive compensation (6/11), auditor ratifications (7/11), and equity incentive plan expansions (2/11), signaling standard proxy season activities amid governance focus. EDAP TMS SA stands out with robust YoY HIFU revenue growth to record levels and new product launches, contrasting neutral/mixed sentiments elsewhere; no widespread period-over-period financial trends evident beyond EDAP's positive revenue and Signet's multi-year pay-vs-performance disclosures spanning FY2022-2026. High materiality events include Origin Materials' liquidation plan (10/10) and Mountain Lake's merger risks (9/10), implying bearish portfolio pressure in materials/SPAC segments. Neutral sentiment prevails (6/11), with mixed (1/11) and negative (2/11) outliers highlighting governance risks like Myomo's declassification proposal. Capital allocation leans toward equity incentives for talent retention, with no dividend/buyback mentions; upcoming June 2026 meetings form a dense catalyst calendar for votes on comp and plans.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 14, 2026

The IPO Pipeline stream shows a surge in SPAC-related activity with 4/6 filings being S-4 registrations for business combinations (Exascale Labs, Puget Energy, McCarthy Finney, Electra Vehicles), alongside two S-1 filings for new SPAC IPOs and follow-ons (Yorkville International, Vivakor), signaling robust de-SPAC and blank-check company momentum on May 14, 2026. Positive sentiment dominates high-materiality deals like Yorkville's $200M IPO and Exascale's merger with 94% voting power retention, while neutral tones prevail in energy-focused filings with multi-period XBRL data (Puget FY2023-2026, Vivakor FY2024-2025). Period-over-period trends are nascent but highlight operational expansions via acquisitions (Vivakor's Endeavor Crude Oct 2024) and divestitures (Jul 2025), with no explicit revenue/margin declines noted across filings. Key implications include potential market re-entry for tech/AI (Electra at $250M valuation) and energy firms via SPACs, with dilution risks from warrants/redemptions and insider-held founder shares. Portfolio-level pattern: 67% of filings tied to SPACs, favoring emerging markets/tech over traditional IPOs, positioning investors for post-effectiveness catalysts.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — May 14, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus), dominant themes include SPAC lifecycle events (IPOs, extensions, Q1 results with interest-driven net income amid operating losses), Indian corporate actions (buybacks signaling confidence, insolvencies/distress proceedings), and mixed Q1 2026 results for operating companies with revenue declines in media/advertising offset by cash generation or M&A boosts. Period-over-period trends show 6/15 detailed 10-Qs with YoY revenue growth (e.g., Healthcare Triangle +166%, AIxCrypto liquidity via note sale), but 5 with declines (Versant -1.1%, SpringBig -1.3%) and widespread margin pressure or loss widening (Cabaletta +21% net loss); SPACs averaged +500% YoY net income from trust interest but expanding deficits. Critical developments like CSX's $5B buyback authorization, Lumen's $2.4B debt refinancing, Mangalore Refinery's ₹212cr refund win, and Onward/Cybertech buybacks highlight capital returns and deleveraging, while insolvencies (AGS Transact, Sir Shadi Lal scheme) flag distress. Portfolio-level patterns reveal SPAC resilience via extensions (GP-Act III to Nov 2026) but going concern risks (Vernal), and Indian firms splitting between bullish buybacks (avg 2.5% share capital) and negative CIRP. Implications: Tactical opportunities in buybacks/refinancings, caution on biotech/media distress, monitor SPAC combinations.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 14, 2026

Across 50 Q1 2026 10-Q filings, overarching themes include mixed sentiment dominated by SPACs (e.g., Inflection Point, SUMA, Sizzle) generating net income from trust interest (avg ~$1-2M per quarter) amid operating losses and cash burn, while operating companies show polarized revenue trends: 12/25 reported YoY growth (avg +70%, led by Healthcare Triangle +166%, BitGo +113%) but 13 saw declines (avg -40%, e.g., New Fortress -52%, Swarmer -82%). Margin compression affected 8/15 detailed cos (avg -150 bps) due to rising opex/R&D, though gross margins expanded in winners like Enovix (+495% gross profit). Balance sheets bolstered by financings/IPOs (e.g., Cabaletta cash +41% QoQ, Swarmer +153%), but cash burn intensified in 20+ cos (avg op cash use $1-3M). Capital allocation leans conservative with distributions up in REITs/BDCs (Blue Owl +7%, Oaktree Gardens +30% YoY), few buybacks. No widespread insider activity reported, but high materiality names (New Fortress 9/10, StubHub 9/10) signal sector rotation potential from energy/tech distress to fintech/REIT recovery. Portfolio implication: overweight revenue accelerators, avoid prolonged cash burners.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 14, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (May 14, 2026 period), overarching themes include aggressive debt refinancing (25+ issuances/amendments totaling billions, e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B) to extend maturities and repay near-term obligations, signaling proactive deleveraging amid higher rates rather than outright insolvency. Explicit distress peaks with Trinseo's $2B debt-cut RSA via pre-pack Chapter 11, Society Pass's Chapter 11 filing, and FREIT's liquidation plan (60-97% premium), representing 6% of filings but high materiality (10/10). Where period data available, trends mixed: Applied Materials +11% YoY revenue, +0.8pts gross margin to 49.9%, EPS +33% YoY contrasts HyOrc/GridAI dilutive raises; no broad insider selling/buying patterns noted. Capital allocation favors refinancings/repayments over dividends/buybacks (e.g., AEP forward sales, Tyler $1.4B notes + repurchases). Forward catalysts cluster in Q3 2026 (acquisitions, closings). Portfolio-level: moderate distress with refinancings mitigating bankruptcy risks, but REIT/energy small caps vulnerable; relative outperformance in semis/utilities.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 14, 2026

Across 24 filings in the USA Executive & Director Changes stream (May 14, 2026), dominant themes include orderly C-suite retirements with named successors in insurance (RenaissanceRe CFO/CPO retire Dec 2026/Jan 2027, Selective CIO retires June 2026), sudden separations without detailed reasons (CSX CTO immediate exit, Ocugen CMO May 8, Xponential COO May 13), and positive board appointments in financials/biotech (AIG independent director June 1, Corbus pharma veteran ahead of ASCO). Capital allocation remains bullish with new $5B CSX share repurchase (atop $989M remaining) and $3B KeyCorp program replacing $1B prior ($280M left), signaling management confidence amid stable dividends. Annual meetings showed strong approvals but pockets of opposition (e.g., CSX director votes 299M against, Fulgent 6M withheld on director). NeoVolta outlier with 262% 9-mo revenue growth to $13.3M despite flat Q3, gross margins +20pp to 46%; no broad YoY/QoQ deterioration but diverse sectors limit portfolio trends. Implications: Succession planning enhances stability (positive for insurers), abrupt exits flag monitoring (COO/CTO roles), buybacks boost returns in transport/banks.

24 high priority 24 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 14, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) Chapter 11 filing by Society Pass Incorporated (SOPA), signaling acute financial distress in the travel and media sectors. No period-over-period financial trends are detailed in the filing, but the voluntary petition implies severe liquidity constraints and operational challenges culminating in bankruptcy on May 12, 2026. Key developments include joint administration in the Southern District of Texas, operations continuing as debtors-in-possession, and a default under the Prepetition Insurance Agreement with automatic stay on enforcement. Equity trading on Nasdaq is deemed highly speculative with substantial risks, likely leading to significant shareholder value erosion. Negative sentiment dominates, with no bullish indicators from insider activity, capital allocation, or forward-looking guidance beyond first-day motions. Portfolio-level implications highlight insolvency risks for small-cap travel/media firms amid economic pressures.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 14, 2026

The 24 filings reveal a surge in boardroom stability through annual meetings (Fulgent, CSX, Cushman, DMC Global, Delcath, InfuSystem) with director elections mostly passing despite notable opposition in Fulgent (up to 6M withheld for Groves) and CSX (299M against Zillmer). Executive transitions dominate, with orderly retirements and appointments (Selective CIO to interim, RenaissanceRe CFO/CPO to internal successors Jan 2027, AIG independent dir Jun 1, Standex CFO promo), but abrupt separations (CSX EVP immediate, Ocugen CMO May 8, Xponential COO May 13) raise flags. Capital allocation shines with CSX's $5B buyback atop $989M remaining and KeyCorp's $3B program replacing $1B ($280M left) plus $0.205 dividend; equity plans approved widely (Fulgent 2M+1.5M shares, Cushman 12M+, Delcath +1.8M). NeoVolta outlier with Q3 revenue flat YoY at $2M but 9-mo +262% to $13.3M, margins 46% vs 26% YoY despite wider $3M loss. Portfolio trends: Positive sentiments in 7/24 (e.g., insurance, fitness), mixed/neutral elsewhere; no broad insider selling but appointments signal conviction. Implications: Bullish for capital returns in financials/transport, monitor governance dissent and transitions for execution risks.

24 high priority 24 total filings
· daily

US Merger & Acquisition SEC Filings — May 14, 2026

The 16 filings reveal a surge in SPAC activity with 10 new or progressing blank check companies (IPOs, unit separations, extensions, and de-SPAC advancements), signaling robust M&A appetite amid a tight deadline environment, while 5 major acquisitions completed on May 14, 2026, across pharma (Apellis/Biogen), telecom (CSG/NEC), marine (Off The Hook/Apex), and homebuilding (Tri Pointe/Sumitomo). Period-over-period trends show SPACs like Boost Run (Willow Lane) posting net income growth to $3.4M in 2025 from $0.1M in 2024 driven by trust interest, but cash declines and widening deficits highlight liquidity strains common to 4/16 filings. Completed deals emphasize accretive synergies (Biogen EPS boost 2027, Off The Hook millions in savings), with forward-looking catalysts like CVRs up to $4/share and Phase 3 data H1 2027. Portfolio-level patterns indicate SPAC extensions averting liquidation (e.g., GP-Act III to Nov 2026), but going concern doubts in 3 SPACs and proxy risks in Mountain Lake underscore execution risks. Market implications include heightened M&A momentum in US equities, favoring acquirers like Biogen and Sumitomo for growth, while SPACs offer de-SPAC alpha if targets materialize.

16 high priority 16 total filings